If so, they may qualify for the ASPECT™ clinical research study. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer’s dementia.
The ASPECT study can help us learn more about a potential treatment for agitation in patients with Alzheimer’s dementia.
Be between the ages of 50 and 90
Have a diagnosis of probable Alzheimer’s dementia
Have moderate-to-severe agitation that interferes with their daily life
Have a reliable caregiver who spends a minimum of 2 hours per day, 4 days per week with them and is willing and able to comply with all study procedures
Other eligibility criteria will apply.
These are just some of the many reasons why more research on the disease is needed.
Your choice regarding cookies on this site
By continuing to access this website you are giving us consent to collect cookies.